Top Stories
The round brings the biotech's total capital raised to $100 million.
The French biotech will use PacBio's HiFi and Kinnex long-read RNA sequencing to generate data from over 10,000 samples.
The biotech has a pair of degraders in Phase I testing for allergic diseases and Graves' disease, respectively.
The CROWN trial evaluated the drug versus daily oral antiretroviral therapy in people with a history of ART and unsuppressed HIV.
"mRNA transformed vaccines, but we believe its greatest potential lies in therapeutics," said co-founder and CEO Miroslav Gasparek.
Conference News
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on develo...
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
MANCHESTER, United Kingdom, Oct. 06, 2026 (GLOBE NEWSWIRE) -- F2G Ltd. today announced abstracts accepted for oral and poster presentation at IDWeek 2026, taking place October 21–24, 2026, at the Walt...
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney diseaseTwo poster presentations will highlight preclinical research supporti...
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesi...
